Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene

被引:550
作者
Holtschke, T
Lohler, J
Kanno, Y
Fehr, T
Giese, N
Rosenbauer, F
Lou, J
Knobeloch, KP
Gabriele, L
Waring, JF
Bachmann, MF
Zinkernagel, RM
Morse, HC
Ozato, K
Horak, I
机构
[1] UNIV WURZBURG,INST VIROL & IMMUNBIOL,D-8700 WURZBURG,GERMANY
[2] UNIV HAMBURG,HEINRICH PETTE INST,HAMBURG,GERMANY
[3] NICHHD,NATL INST HLTH,LAB MOL GROWTH REGULAT,BETHESDA,MD 20205
[4] UNIV ZURICH,INST EXPT IMMUNOL,CH-8091 ZURICH,SWITZERLAND
[5] NIAID,NATL INST HLTH,IMMUNOPATHOL LAB,BETHESDA,MD 20205
[6] RES INST MOL PHARM,DEPT MOL GENET,D-12207 BERLIN,GERMANY
关键词
D O I
10.1016/S0092-8674(00)81348-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interferon consensus sequence binding protein (ICSBP) is a transcription factor of the interferon (IFN) regulatory factor (IRF) family. Mice with a null mutation of ICSBP exhibit two prominent phenotypes related to previously described activities of the IRF family. The fi rst is enhanced susceptibility to virus infections associated with impaired production of IFN gamma. The second is deregulated hematopoiesis in both ICSBP-/- and ICSBP+/- mice that manifests as a syndrome similar to human chronic myelogenous leukemia. The chronic period of the disease progresses to a fatal beast crisis characterized by a clonal expansion of undifferentiated cells. Normal mice injected with cells from mice in blast crisis developed acute leukemia within 6 weeks of transfer. These results suggest a novel role for ICSBP in regulating the proliferation and differentiation of hematopoietic progenitor cells.
引用
收藏
页码:307 / 317
页数:11
相关论文
共 41 条